Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5606733 | 0.74 | GRM2 (0.49) | GRM2 | |
| SCHEMBL29446495 | 0.74 | GRM2 (0.49) | GRM2 | |
| SCHEMBL15368158 | 0.73 | CYP3A4 (0.33) | CYP3A4GRM2GRM3 | |
| SCHEMBL19203383 | 0.68 | CYP3A4 (0.41) | CYP3A4GRM2GRM3 | |
| SCHEMBL5558359 | 0.68 | CYP3A4 (1.00) | CYP3A4GRM2GRM3 | |
| SCHEMBL5563167 | 0.67 | CYP3A4 (0.77) | CYP3A4GRM2 | |
| SCHEMBL29446492 | 0.67 | CYP3A4 (0.74) | CYP3A4GRM2GRM3 | |
| SCHEMBL17348236 | 0.67 | CYP3A4 (0.74) | CYP3A4GRM2GRM3 | |
| SCHEMBL17336828 | 0.67 | CYP3A4 (0.74) | CYP3A4GRM2GRM3 | |
| SCHEMBL5558255 | 0.66 | CYP3A4 (0.82) | CYP3A4GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211658-A1 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH SLEEP SPINDLE DEFICITS | THE BROAD INSTITUTE, INC. (US) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211658-A1 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH SLEEP SPINDLE DEFICITS | HCRTR2, GRIN2A, GRM2 | CYP3A4 4478/4885GRM2 3/4885GRM3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.